|
 "I stay in my lane. I'm not a politician. I do public health
things," he said in an interview on Thursday ahead of next week's
Reuters Total Health conference.
Since January, Fauci has served on President Donald Trump's White
House Coronavirus Task Force, a position that has frequently put him
at odds with the president, who has sought to downplay the pandemic
and focused instead on opening the economy.
"There's absolutely no reason and no sense at all for me to stop
doing something in the middle of a pandemic that is playing a major
role in helping us get out of the pandemic," Fauci said.
His advice for the president-elect, he said, is "exactly the same"
as what he is recommending now - social distancing, avoiding crowds,
wearing masks, washing hands. "Public health principles don't change
from one month to another or from one administration to another."
Fauci has served six administrations and came to prominence fighting
the AIDS epidemic in the 1980s under President Ronald Reagan.
His "day job" is developing vaccines and therapeutics as director of
the National Institute of Allergy and Infectious Diseases, work that
is starting to bear fruit.
On Monday, Pfizer Inc <PFE.N> and German partner BioNTech SE
<22UAy.F> announced that their experimental coronavirus vaccine was
more than 90% effective - significantly higher than most experts had
anticipated.
Moderna Inc <MRNA.O>, a company developing a similar vaccine with
support from the White House's Operation Warp Speed program, is
expected to report results from their late-stage vaccine trial in
the next week or so.
[to top of second column] |
Both vaccines use messenger RNA (mRNA) technology, an entirely new rapid vaccine
platform that uses synthetic genes to trigger an immune response. Older methods
typically use some form of inactivated or killed virus particles.
"It was a home run for the Pfizer product, more than 90% - close to 95% -
effective. I have every reason to believe that the Moderna product is going to
be similar," Fauci said.
"It's an almost identical platform to the Pfizer vaccine, so I would not be
surprised at all if it was highly effective," Fauci added.
The next big question about mRNA technology is safety. Fauci took as a good sign
the fact that neither the Pfizer trial, which has enrolled more than 43,000
people so far, nor the Moderna trial, which involves 30,000, had to pause to
investigate safety issues.
"That's really good news," he said. People in both trials will be followed for
two years to make sure there are no long-term side effects. Barring that, "I
think that the mRNA platform is here to stay," he predicted.
In spite of the high bar set by the Pfizer vaccine so far, Fauci said he
believes there is still "plenty of room for multiple vaccines, even though there
may be a modest degree of difference in total efficacy."
For more on Reuters Events Total Health click here:
https://reutersevents.com/
events/healthcare/
(Reporting by Julie Steenhuysen, Editing by Peter Henderson and Bill Berkrot)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
